1.Effects of berberine hydrochloride on secretion of interleukin-6 from human periodontal ligament cells cultured in vitro
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(01):-
Objective To observe the effects of berberine hydrochloride on the secretion of interleukin-6(IL-6)from human periodontal ligament cells(PDLCs)cultured in vitro.Methods Periodontal ligament tissues were isolated from extracted human premolars,and PDLCs were cultured in vitro.After identification by immunohistochemistry technique,human PDLCs were divided into LPS group and NLPS group according to whether lipopolysaccharide(LPS,50 ?g/mL)was contained in cell culture media.Then in accordance with the final concentrations of berberine hydrochloride in cell culture media(0,0.010,0.020,and 0.030 g/L),the groups were subdivided into LPS and NLPS control group,LPS1 and NLPS1 group,LPS2 and NLPS2 group,LPS3 and NLPS3 group.IL-6 contents in supernatants of each group were determined by enzyme-linked immunosorbent assay,and statistical analysis and comparison were conducted as well.Results Compared with corresponding LPS and NLPS groups,IL-6 contents in supernatants of LPS3 group and NLPS3 group reduced markedly(P
2.Application of bone transmission and fascia skin flap recover large defeciency of bone and soft tissue of lower limb
Zhigang ZHANG ; Yu WANG ; Hai LI
Orthopedic Journal of China 2006;0(08):-
[Objective]To research the effect of using Ilizarov technique in bone transmission and fascia skin flap for large defeciency of bone and soft tissues of lower limb.[Method]There were 12 patients in our group,11 patients had severe compound trauma of the leg,one in arm.Bone defeciency range was 4~12 cm,average 8 cm,cotaneous defeciency was 4?5 cm2~14?5 cm2,and all of them had acute infection.Nine had been treated with leg lateral fascia skin flap,1 had been treated with leg fascia skin flap,1 had been treated with the opposide leg skin flap,1 had been treated with the arm fascia skin flap,in 12 bone transport,elongation range was 4~12 cm,average 8 cm.Eight had been used double arms external fixation device,4 cases had been used circle shape external fixation device.[Result]Totally 12 patients were followed up for 2~10.8 years(average,4.2 years) elongation part and compressed part healed naturally,all of the fascia shin flap were alive.No bone ununion and chronic osteomyelitis appeared.[Conclusion]Using Ilizarov bone transport technique and fascia skin flap is a good way for treating large defeciency of bone and soft tissue.Its advantages:(1)The wound limb can maintain stability by external fixatian device.The methed of the bone transportation can fill big section bone deficiency;(2) In the same time the fascia shin flap may be transported,and repair soft tissue deficiency,provide good condition to bone's healing and control infection;(3)The external fixation device can provide distraction and compression functions,this function makes elongation part and compressed part obtain the reasonable biomechanics condition which would be good to bone healing;(4)The course of bone transmission can stimulate bone repair mechanisms,to enhance the wound limb metabolism,increase blood supply circularation,the grown bone factor aggregation,enhance the body's initiative repair mechanisms and infection controlling mechanism;(5)In the protection of the external fixation device,the patient's wound limb can do early rehabilitation,thus can avoid osteoporosis and joint dyfunction because of the lone-term immobility;(6)To use these methods,the treatment period will be shortened,antibiotic application will be decreased,the treatment cost will be lower than other methods and complications will be decreased as well.
3.Clinical analysis of thermal burns induced by amide and nitro compounds of benzene.
Yuan-hai ZHANG ; Qing-qing YU ; Zhi-hua SHAO
Chinese Journal of Industrial Hygiene and Occupational Diseases 2010;28(9):707-708
Adult
;
Amides
;
adverse effects
;
Benzene
;
adverse effects
;
Burns, Chemical
;
pathology
;
therapy
;
Female
;
Humans
;
Male
;
Middle Aged
;
Nitro Compounds
;
adverse effects
;
Young Adult
7.Effect of diameter-controlled Ti-TiO2 nanotubes on the adhesion of osteoblast and fibroblast.
Hong-cai LI ; Yu-mei ZHANG ; Hai-ping SUN
Chinese Journal of Stomatology 2012;47(2):122-126
OBJECTIVETo study the effect of Ti-TiO2 nanotubes with different diameters on the adhesion of fibroblast and osteoblast, and to find which diameter was more favorable for cells' respective adhesion.
METHODSPure titanium sheets were polished and then anodized at different potentials for 1 h with Ti as anode and Pt as cathode. TiO2 nanotubes formed at 1, 5, 10 and 20 V potentials served as experimental groups and polished pure titanium served as control group. Field emission scanning electron microscopy (Fe-SEM) was used to analyze the surface topography. Stained nucleus with Hoechst33342 were used to measure the cell adhesion. The cell shape on the sample surface were analyzed with Fe-SEM.
RESULTSTiO2 nanotube array of different inner diameters from 15 nm to 100 nm were grown on titanium sheets by anodization at potentials from 1 to 20 V. At 30, 60 and 120 min, fibroblast adhesion at nanotubes anodized at 5 V was (141 ± 9), (388 ± 14) and (489 ± 15) respectively, significantly less than any other nanotube surface at the same time (P < 0.01). Nanotubes anodized at 20 V had the least inhibitory effect for fibroblast adhesion with a number of (579 ± 14) at 120 min, and the cell shape was also inhibited. At 30, 60 and 120 min, osteoblast had a significant better adhesion on nanotubes formed at 5 V than it did on any other surface at the same time (P < 0.01), except the control group at 30 min, with the adhesion number of (198 ± 10), (431 ± 10) and (501 ± 10) respectively, and osteoblast had a abundant spread on nanotubes formed at 5 V; while osteoblast adhesion on nanotubes anodized at 20 V was (152 ± 11), (403 ± 9) and (465 ± 12) respectively, less than on any other nanotube surface within the same time (P < 0.05), and the cell shape on the surface changed to be more elongate.
CONCLUSIONSFibroblast adhesion is inhabited more or less on Ti-TiO2 nanotubes of different diameters. Nanotubes formed at 5 V have the most osteoblast adhesion, and inhibit fibroblast adhesion.
Animals ; Cell Adhesion ; Fibroblasts ; cytology ; ultrastructure ; Mice ; Microscopy, Electron, Scanning ; Nanotubes ; chemistry ; Osteoblasts ; cytology ; ultrastructure ; Surface Properties ; Titanium ; chemistry
8.Limited Septoplasty Under Nasal Endoscopy
yun-hai, FENG ; shan-kai, YIN ; yu-jun, ZHANG
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(01):-
Objective To compare the outcomes of powered-assisted septoplasty with CO_ 2 laser-assisted septoplasty. Methods Thitry patients with limited deviation of nasal septum were analyzed retrospectively. Among 30 patients, 18 underwent powered-assisted septoplasty and the rest underwent CO_ 2 laser-assisted septoplasty. The surgical results were assessed by the visual analogue scale (VSA) and acoustic rhinometry. Results VSA scores significantly improved in both groups after surgery (P
9.Construction and application of storehouse for medical camp in emergency support brigade
Jiming ZHANG ; Cunhe LIN ; Ling WANG ; Hai YU ; Leihan LIU
Chinese Medical Equipment Journal 2004;0(09):-
The framed storehouse and the open rolling shutter door equipment are designed and manufactured for the infrastructure construction.The multipurpose and moved frame operating platform is designed and manufactured according to the demands of loading and unloading as a whole for part medical equipments.In this way,the shortage of the storehouse space is solved and the usual training and moving become easier.
10.Prevention and treatment of HBV recurrence with lamivudine in HBsAg positive renal allograft recipients
Ya-Wang TANG ; Yu-Hai ZHANG ; Ye TIAN ;
Chinese Journal of Organ Transplantation 2005;0(07):-
Objective To analyze the effect of prevention and treatment with lamivudine in HBsAg positive renal allograft recipients with HBV recurrence.Methods In 28 patients with chronic renal failure whose HBsAg was positive,8 cases were positive for HBV-DNA positive.All these 28 cases had normal liver function without hepatic cirrhosis before renal transplantation.All donors were negative for HBsAg.Twenty patients received lamivudine prophylactic treatment:14 cases positive for HBsAg but negative for HBV-DNA before transplantation received lamivudine treatment immedia- tely after transplantation and 6 cases positive for both HBsAg and HBV-DNA received lamidudine treatment before transplantation.Eight patients were treated with lamivudine when their hepatic dys- function with recurrent HBV antigenemia were developed after transplantation.Lamivudine was orally taken and its initial dosage was 100 rag/day.Results The follow-up period of the 28 patients were 13- 54 months with the average of 23.6 months,and 2 died during this period.Mild hepatic dysfunction with recurrent HBV antigenemia developed in 3 of 20 hepatitis antigenemia patients received lamivu- dine prophylactic treatment with a mean duration of 9.3 months after transplantation.The highest average level of serum ALT was 87.5 U/L.The liver function returned to the normal with HBV-DNA negative after lamivudine treatment in 3 patients.The other 17 patients maintained normal liver func- tion with HBV-DNA negative during the follow-up period.Hepatic dysfunction with recurrent HBV antigenemia(or HBV-DNA titer increased significantly)developed with a mean duration of 4.6 months in all 8 patients without receiving lamivudine prophylactic treatment.The highest average level of serum ALT was 174.5 U/L.The liver function returned to the normal with HBV-DNA negative after larnivudine treatment in the 8 cases.HBV-DNA,however,reappeared in 5 eases without any dis- continuation of lamivudine.The creatinine level remained normal without any severe drug side effects in 28 patients during lamivudine treatment.Conclusion Lamivudine treatment before hepatic dysfunc- tion might be a safe and effective strategy for prevention of recurrence of hepatitis B viremia in HBsAg positive renal allograft recipients.